W. Sasiela

发表

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

E. Tuzcu, P. Schoenhagen, S. Nissen, 2005 .

High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial

W. Sasiela, J. Witztum, S. Tsimikas, 2004, Circulation.

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

C. Cannon, W. Sasiela, H. Surks, 2016, Journal of the American Heart Association.

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

J. Mckenney, D. Rader, W. Sasiela, 2008, Nature Clinical Practice Cardiovascular Medicine.

High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study

P. Libby, N. Rifai, W. Sasiela, 2003, Circulation.

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

D. Gaudet, D. Rader, R. Hegele, 2013, The Lancet.

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

M. Ezekowitz, D. Waters, W. Sasiela, 2005, European heart journal.

Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

P. Libby, N. Rifai, W. Sasiela, 2004, Circulation.

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

J. Jukema, W. Sasiela, U. Schwahn, 2014, Journal of Lipid Research.

1117-88 High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: Results from the MIRACL trial

M. Ezekowitz, D. Waters, W. Sasiela, 2004 .

Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers

W. Sasiela, M. Emery, B. Amore, 2021, Clinical and translational science.

ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.

D. Gaudet, P. Shah, D. Brisson, 2017, The New England journal of medicine.

Impact of the MTP Inhibitor AEGR-733 on Pharmacokinetics of Statins

D. Rader, W. Sasiela, R. Movva, 2007 .

Impact of high doses of the MTP-Inhibitor, AEGR-733, on the single dose Pharmacokinetics of Atorvastatin and Rosuvastatin

D. Rader, W. Sasiela, L. Bloedon, 2007 .

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.

P. Libby, D. Grobbee, P. Thompson, 2020, American heart journal.

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

A. Lichtenstein, W. Sasiela, R. Nandakumar, 2017, Circulation.

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).

Jennifer G. Robinson, D. Gaudet, G. Watts, 2017, The American journal of cardiology.

Cellular Models of Atherosclerosis in the Young a

W. Sasiela, S. Fowler, PERRY D. Gasquecarter, 1991, Annals of the New York Academy of Sciences.

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics

Christina M. Friedrich, W. Sasiela, J. Barrett, 2017, Gene regulation and systems biology.

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.

J. Mckenney, C. Cannon, J. Robinson, 2016, Journal of clinical lipidology.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2years

Jennifer G. Robinson, J. Robinson, W. Sasiela, 2018 .

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.

Lawrence A Leiter, A. Gotto, M. Banach, 2020, Journal of clinical lipidology.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Deepak L. Bhatt, R. Diaz, H. White, 2018, New England Journal of Medicine.

Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model

G. Watts, S. Jadhav, W. Sasiela, 2021, European heart journal. Cardiovascular pharmacotherapy.

Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.

R. D'Agostino, C. Cannon, J. Massaro, 2019, American Heart Journal.

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Tanya M. Teslovich, D. Ledbetter, S. McCarthy, 2017, The New England journal of medicine.

Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.

C. Cannon, W. Sasiela, R. Rosenson, 2019, The American journal of cardiology.

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

W. Sasiela, R. McQueen, K. Ray, 2022, American Journal of Cardiovascular Drugs.

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Jennifer G. Robinson, J. Robinson, W. Sasiela, 2017, Journal of the American College of Cardiology.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Deepak L. Bhatt, R. Diaz, H. White, 2018, The New England journal of medicine.

Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.

W. Sasiela, U. Schwahn, D. Blom, 2014, Journal of the American College of Cardiology.

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

Paul Schoenhagen, John Tsai, Tim Crowe, 2005, The New England journal of medicine.

New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk

Jennifer G. Robinson, G. De Backer, C. Shear, 2018, European heart journal. Cardiovascular pharmacotherapy.

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

W. Sasiela, S. Mellis, P. Banerjee, 2019, Circulation.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years.

Jennifer G. Robinson, W. Sasiela, H. Colhoun, 2017, Journal of clinical lipidology.

Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.

W. Sasiela, A. Olsson, G. Schwartz, 2005, Diabetes care.

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

Matthew R. Reynolds, Robert J. Sanchez, C. Cannon, 2017, JAMA cardiology.

Alirocumab, monoclonal antibody to PCSK9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in apoe*3leiden.cetp mice

J. Jukema, W. Sasiela, U. Schwahn, 2014 .

Plaque stabilization: Can we turn theory into evidence?

Peter Libby, P. Libby, W. Sasiela, 2006, The American journal of cardiology.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

J Wouter Jukema, Deepak L. Bhatt, Deepak L Bhatt, 2018, The New England journal of medicine.

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.

D. Grobbee, P. Thompson, J. Kastelein, 2023, The New England journal of medicine.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Deepak L. Bhatt, R. Diaz, H. White, 2014, American heart journal.

Assessing the Equivalence of Paper, Mobile Phone, and Tablet Survey Responses at a Community Mental Health Center Using Equivalent Halves of a ‘Gold-Standard’ Depression Item Bank

W. Sasiela, B. Brodey, I. Brodey, 2017, JMIR mental health.

Abstract: P471 IMPACT OF THE MTP-INHIBITOR AEGR-733 ON THE SINGLE-DOSE PHARMACOKINETICS OF EXTENDED-RELEASE NIACIN

D. Rader, W. Sasiela, R. Movva, 2009 .

Abstract: P469 IMPACT OF HIGH DOSES OF THE MTP-INHIBITOR, AEGR-733, ON THE SINGLE DOSE PHARMACOKINETICS OF ATORVASTATIN AND ROSUVASTAIN

D. Rader, W. Sasiela, L. Bloedon, 2009 .

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

J. Paulauskis, P. Milos, W. Sasiela, 2005, The Pharmacogenomics Journal.

Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials.

M. Banach, W. Sasiela, A. Gotto, 2023, Atherosclerosis.

Pharmacokinetics of bempedoic acid in patients with renal impairment

W. Sasiela, M. Emery, B. Amore, 2021, Clinical and translational science.

Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3

W. Sasiela, S. Mellis, P. Banerjee, 2016 .

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

W. Sasiela, C. Hanotin, Jacques Rey, 2014, Cardiovascular therapeutics.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Deepak L. Bhatt, R. Diaz, H. White, 2014, American heart journal.

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Jennifer G. Robinson, W. Sasiela, R. Rosenson, 2017, Journal of the American College of Cardiology.

High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study

P. Libby, N. Rifai, W. Sasiela, 2003, Circulation.

Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/kexin Type 9: Therapeutic Dosing in Phase 3 Studies

W. Sasiela, H. Ginsberg, R. Pordy, 2013 .

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.

Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.

W. Sasiela, Shaun G. Goodman, Stephen J. Nicholls, 2024, Journal of the American College of Cardiology.

High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study

P. Libby, N. Rifai, W. Sasiela, 2003, Circulation.

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

H. Huikuri, H. Suryapranata, A. Bagai, 2024, European heart journal. Cardiovascular pharmacotherapy.

Abstract 16127: Effect of REGN727/SAR236553 Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Fully Human Monoclonal Antibody in Patients with Elevated Triglycerides/Low High-Density Lipoprotein Cholesterol: Data from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443)

W. Sasiela, H. Ginsberg, R. Dufour, 2012 .